This Core provides coordination and integration for all other cores, satellites and projects and acts to insure that the research and programmatic goals of the Center are met. The administrative leadership consists of the Program Director, two Associate Directors, and the Executive Director. They are assisted by the Executive Committee that includes these individuals, leaders of the Cores and Projects and other senior faculty. The Administration Core supports, monitors and coordinates the activities of all components of the ADRC.
The specific aims of Core A: Administration are: 1. To establish and maintain administrative structure and governance, including budgetary oversight, future planning, and optimal resource utilization, to meet the overall goals of the Center. 2. To coordinate and integrate all ADRC activities and components (Cores, Satellites, Projects, Pilot projects) for research, training, information transfer, and resource sharing. 3. To promote scientific and educational interactions (including public relations) and collaborations on Alzheimer's disease (AD) and related conditions at all levels with other faculty at Washington University, other Alzheimer's Disease Centers, the National Alzheimer Coordinating Center (NACC), National Institute on Aging (NIA), and the Alzheimer's Association, locally and nationally. 4. To solicit, evaluate, select, and monitor Pilot Projects. 5. To provide for periodic external review of the ADRC. 6. To provide assurance of compliance with human subjects, animal welfare, scientific integrity, and the policy requirements of Washington University and the National Institutes of Health (NIH) regarding data sharing and public access to research findings.
|Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90|
|Staley, Lyndsay A; Ebbert, Mark T W; Bunker, Daniel et al. (2016) Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels. BMC Genomics 17 Suppl 3:439|
|Ebbert, Mark T W; Staley, Lyndsay A; Parker, Joshua et al. (2016) Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels. BMC Genomics 17 Suppl 3:437|
|Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082|
|Gordon, Brian A; Blazey, Tyler; Su, Yi et al. (2016) Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol 73:1192-1200|
|Lucey, Brendan P; Mcleland, Jennifer S; Toedebusch, Cristina D et al. (2016) Comparison of a single-channel EEG sleep study to polysomnography. J Sleep Res 25:625-635|
|Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962|
|Saint-Aubert, Laure; Pariente, JÃ©rÃ©mie; Dumas, Herve et al. (2016) Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man. BMC Neurol 16:122|
|Cummings, Jeffrey; Aisen, Paul S; DuBois, Bruno et al. (2016) Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther 8:39|
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8|
Showing the most recent 10 out of 715 publications